Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Group has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing, its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high value added activities or companies in the pharmaceutical, biotech or medtech field.
Subscribe to our email newsletter
Debiopharm Research & Manufacturing boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity. The objective today is to expand industrial operations in Martigny by acquiring opportunities for optimization and production, generating a double-digit million revenue annually.
Expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe are some of the features that will enable this objective to be met.
Debiopharm Group board delegate Thierry Mauvernay noted the company has invested heavily during the last years to automate its site in Martigny as much as possible.
"Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development," Mauvernay added.